Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Dash

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Vox Sanguinis|July 14, 2001
Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injectionG P Mould, J A Sutton, P Matejtschuk, et al.
The Practitioner|March 1, 1982
A new dry powder inhalerG M Pover, A K Browning, B M Mullinger, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 1984
Extraction of ceftazidime in boneS P Hughes, I D McCarthy, R M Fleming, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 1986
The volume of distribution of ceftazidime and albumin in normal, immature and infected boneM R Pinto, R H Fleming, S P Hughes, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2011
Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia AM Matysiak, H Bobrowska, W Balwierz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2011
Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgeryC R M Hay, A Hellmann, A Dmoszynska, et al.
Thorax|May 1, 1980
Sputum and blood concentrations of cefuroxime in lower respiratory tract infectionC W Havard, R P Bax, T C Samanta, et al.
Clinical and Experimental Immunology|August 8, 2007
The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodiesG E Chapman, J R Ballinger, M J Norton, et al.
Clinical and Experimental Immunology|November 13, 2010
Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseasesJ N Moy, A M Scharenberg, M R Stein, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Vox Sanguinis|July 14, 2001
Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injectionG P Mould, J A Sutton, P Matejtschuk, et al.
The Practitioner|March 1, 1982
A new dry powder inhalerG M Pover, A K Browning, B M Mullinger, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 1984
Extraction of ceftazidime in boneS P Hughes, I D McCarthy, R M Fleming, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 1986
The volume of distribution of ceftazidime and albumin in normal, immature and infected boneM R Pinto, R H Fleming, S P Hughes, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2011
Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia AM Matysiak, H Bobrowska, W Balwierz, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2011
Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgeryC R M Hay, A Hellmann, A Dmoszynska, et al.
Thorax|May 1, 1980
Sputum and blood concentrations of cefuroxime in lower respiratory tract infectionC W Havard, R P Bax, T C Samanta, et al.
Clinical and Experimental Immunology|August 8, 2007
The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodiesG E Chapman, J R Ballinger, M J Norton, et al.
Clinical and Experimental Immunology|November 13, 2010
Efficacy and safety of a new immunoglobulin G product, Gammaplex(®), in primary immunodeficiency diseasesJ N Moy, A M Scharenberg, M R Stein, et al.
Pageof 5